# Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults

> **NCT01889173** · PHASE1 · COMPLETED · sponsor: **Tonix Pharmaceuticals, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Healthy Adults

## Interventions

- **DRUG:** TNX-102 SL Tablets at 2.8 mg
- **DRUG:** TNX-102-B SL Tablets at 2.8 mg
- **DRUG:** TNX-102-C SL Tablets at 2.8 mg
- **DRUG:** Cyclobenzaprine tablets

## Key facts

- **NCT ID:** NCT01889173
- **Lead sponsor:** Tonix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2013-12
- **Final completion:** 2014-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01889173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01889173, "Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01889173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*